Edgar Filing: VENTAS INC - Form 424B7

VENTAS INC Form 424B7 December 01, 2009

> Filed pursuant to Rule 424(b)(7) Registration No. 333-141605

## **PROSPECTUS SUPPLEMENT NO. 20**

(To prospectus dated March 27, 2007)

1,819,582 Shares

Ventas, Inc.

Common Stock

This prospectus supplement no. 20, which supplements the prospectus filed by us on March 27, 2007, as supplemented on April 11, 2007, May 14, 2007, June 12, 2007, July 2, 2007, August 10, 2007, August 31, 2007, September 21, 2007, October 9, 2007, November 1, 2007, December 11, 2007, January 23, 2008, March 14, 2008, April 7, 2008, June 25, 2008, July 31, 2008, October 7, 2008, October 28, 2008, May 11, 2009, and May 29, 2009, relates to the resale from time to time by selling stockholders of the shares of common stock that may be issued to them upon the conversion of our 3 7/8% Convertible Senior Notes due 2011.

You should read this prospectus supplement in conjunction with the related prospectus, including any amendments or supplements thereto, which should be delivered in conjunction with this prospectus supplement. This prospectus supplement is not complete without, and may not be delivered or used except in conjunction with the prospectus, including any such amendments or supplements. This prospectus supplement is qualified by reference to the prospectus, as previously supplemented, except to the extent that the information provided by this prospectus supplement supercedes information contained in the prospectus, as previously supplemented.

You should read and rely only on the information contained in this prospectus supplement and the related prospectus, as previously supplemented, together with additional information described on page 8 of the related prospectus under the heading Where You Can Find More Information and Incorporation by Reference. Neither we nor the selling stockholders have authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor the selling stockholders are making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained or incorporated by reference in this prospectus supplement or the related prospectus, as previously supplemented, is accurate only as of the date of the documents containing the information.

Investing in our common stock involves risks. See Risk Factors beginning on page 1 of the related prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities or passed upon the accuracy or adequacy of this prospectus supplement or the related prospectus. Any representation to the contrary is a criminal offense.

The information appearing under the heading Selling Stockholders beginning on page 3 of the related prospectus, as previously supplemented, is amended and restated in its entirety by the information below.

## SELLING STOCKHOLDERS

Our 3 7/8% Convertible Senior Notes due 2011 (the notes) were originally issued by us to and immediately resold by Banc of America Securities LLC and J.P. Morgan Securities, Inc. in transactions exempt from the registration requirements of the Securities Act to persons reasonably believed by the initial purchasers to be qualified institutional buyers as defined by Rule 144A under the Securities Act. Selling stockholders, including their transferees, pledgees, donees and successors, may from time to time offer and sell pursuant to this prospectus and any accompanying prospectus supplement any or all of the shares of our common stock that we may issue upon the conversion of the notes.

The table below sets forth the name of each selling stockholder and the number of shares of our common stock that would become beneficially owned by each selling stockholder should we issue our common stock that may be offered pursuant to this prospectus upon conversion of the notes. We have prepared the table below based on information provided to us by or on behalf of the selling stockholders on or prior to November 30, 2009. The selling stockholders may offer all, some or none of the shares of our common stock that we may issue upon the conversion of the notes. Accordingly, we cannot estimate the number of shares of our common stock that will be held by the selling stockholders upon consummation of any of these sales. In addition, the selling stockholders identified below may have acquired, sold, transferred or otherwise disposed of, in transactions exempt from the registration requirements of the Securities Act, all or a portion of their notes or shares of our common stock since the date on which they provided the information regarding their notes.

The number of shares of our common stock issuable upon the conversion of the notes shown in the table below assumes conversion of the full amount of notes held by each selling stockholder at the initial conversion rate of 22.1867 shares of our common stock per \$1,000 principal amount of notes and a cash payment in lieu of any fractional share, assuming 10% annual growth in our dividend rate and 25% quarterly growth in the market price of our common stock. Effective September 9, 2009, the conversion rate was adjusted to 22.8842 shares per \$1,000 principal amount of notes and is subject to further adjustment in certain events. Accordingly, the number of shares of our common stock issued upon the conversion of the notes may increase or decrease from time to time. The number of shares of our common stock owned by the selling stockholders or any future transferee from any such holder assumes that they do not beneficially own any shares of common stock other than the common stock that we may issue to them upon the conversion of the notes.

Based upon information provided by the selling stockholders, none of the selling stockholders or their affiliates has, or within the past three years has had, any material relationship with us or any of our predecessors or affiliates.

To the extent any of the selling stockholders identified below are broker-dealers, they may be deemed to be, under interpretations of the staff of the Commission, underwriters within the meaning of the Securities Act.

Information about the selling stockholders may change over time. Any changed information will be set forth in supplements to this prospectus, if required.

	Principal Amount of Notes Owned Prior	Number of Shares Beneficially Owned Prior	Number of Shares Being	Number of Shares Beneficially Owned After	Percentage of Shares Outstanding
Name of Selling Stockholder	to Offering	to Offering	Offered	Offering (1)	(1)(2)
Advent Convertible Arb Master	\$ 4,558,000	36,059	36,059		*
Alcon Laboratories	493,000	3,900	3,900		*
AQR DELTA Master Account, L.P. (3)	500,000	3,955	3,955		*

## Edgar Filing: VENTAS INC - Form 424B7

Name of Selling Stockholder	Principal Amount of Notes Owned Prior to Offering	Number of Shares Beneficially Owned Prior to Offering	Number of Shares Being Offered	Number of Shares Beneficially Owned After Offering (1)	Percentage of Shares Outstanding (1)(2)
AQR DELTA Sapphire Fund, L.P. (3)	500,000	3,955	3,955		*
Aristeia International Limited	9,883,000	78,186	78,186		*
Aristeia Partners LP	8,117,000	64,215	64,215		*
Arizona State Retirement Core Plan (4)	85,000	672	672		*
Arlington County Employees Retirement System	707,000	5,593	5,593		*
Basso Fund Ltd.	340,000	2,689	2,689		*
Basso Holdings Ltd.	5,765,000	45,608	45,608		*
Basso Multi-Strategy Holding Fund Ltd.	4,395,000	34,769	34,769		*
BNP Paribas Arbitrage (5)	2,000,000	15,822	15,822		*
British Virgin Islands Social Security Board	163,000	1,289	1,289		*
Canyon Capital Arbitrage Master Fund, Ltd. (6)	2,720,000	21,518	21,518		*
Canyon Value Realization Fund, L.P. (6)	1,440,000	11,392	11,392		*
Canyon Value Realization MAC 18 Ltd. (6)	160,000	1,265	1,265		*
Citigroup Global Markets Inc. (7)	17,000,000	134,490	134,490		*
CNH CA Master Account, L.P. (3)	1,000,000	7,911	7,911		*
CQS Convertible and Quantitative Strategies Master Fund					
Limited	11,500,000	90,978	90,978		*
Credit Industriel Et Commercial	2,500,000	19,777	19,777		*
DBAG London (8)	6,000,000	47,467	47,467		*
DB RREEF Reflex Master Portfolio LTD (8)	5,000,000	39,556	39,556		*
Domestic & Foreign Missionary Society DFMS	92,000	727	727		*
Deutsche Bank Securities (7)	350,000	2,768	2,768		*
FFVA Mutual Insurance Company	45,000	356	356		*
Fidelity Financial Trust: Fidelity Convertible Securities Fund					
(9)	12,000,000	94,934	94,934		*
Fidelity Financial Trust: Fidelity Strategic Dividend & Income					
Fund (9)	9,550,000	75,551	75,551		*
Fidelity Fixed-Income Trust: Fidelity High Income Fund (9)	14,285,000	113,011	113,011		*
Fidelity Institutional High Yield Fund (4)	600,000	4,746	4,746		*
Florida Fruit & Vegetable Association	69,000	545	545		*
Georgia Municipal Employee Benefit System	985,000	7,792	7,792		*
GLG Market Neutral Fund	20,000,000	158,224	158,224		*
GMIMCO Trust	500,000	3,955	3,955		*
Grady Hospital Foundation	135,000	1,068	1,068		*

## Edgar Filing: VENTAS INC - Form 424B7

Name of Selling Stockholder	Principal Amount of Notes Owned Prior to Offering	Number of Shares Beneficially Owned Prior to Offering	Number of Shares Being Offered	Number of Shares Beneficially Owned After Offering (1)	Percentage of Shares Outstanding (1)(2)
Highbridge Convertible Arbitrage Master Fund LP	5,000,000	39,556	39,556		*
Highbridge International LLC	15,000,000	118,668	118,668		*
HFR CA Opportunity Master Trust	232,000	1,835	1,835		*
Independence Blue Cross	561,000	4,438	4,438		*
JPMorgan Securities, Inc. (7)	671,000	6,341	5,308	1,033	*
KBC Financial Products USA Inc. (7)	3,200,000	25,315	25,315		*
LDG Limited	222,000	1,756	1,756		*
Linden Capital LP	5,000,000	39,556	39,556		*
Luxor/Canyon Capital Arbitrage Fund Ltd. (6)	2,000,000	15,822	15,822		*
Lyxor Master Trust Fund	210,000	1,661	1,661		*
Merrill Lynch, Pierce, Fenner & Smith Incorporated (7)	6,300,000	49,840	49,840		*
MSS Convertible Arbitrage 1 Fund c/o TQA Investors, LLC	49,000	387	387		*
Nuveen Preferred & Convertible Multi-Strategy #1	250,000				